Roxithromycin penetration into skin suction blister fluid following multiple doses

E. Concia, M. Cruciani, V. Monzillo, N. Barzaghi, F. Bartucci, D. Sassella

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Roxithromycin (ROX) concentrations in plasma, skin blister fluid (SBF), and saliva were investigated in six healthy male subjects after administration of 150 mg every 12 hours for 3.5 days (seven doses). Mean peak plasma concentration after the last dose was 5.4 ± 1.3 mg/L (range, 2.8 to 10.0 mg/L) and was attained at a mean time of 1.3 ± 0.2 hours. From the plasma concentration-time curve after the last dose the following pharmacokinetic parameters were calculated: elimination rate constant, 0.043 ± 0.005 L/hr; elimination half-life, 17.5 ± 2.2 hr; area under the concentration-time curve from zero to infinity; 106.4 ± 6.9 mg/L · hr. ROX showed a good penetration into SBF; the mean SBF/plasma concentration ratio ranged from 47% to 106% at two and 24 hours after administration, respectively. The mean penetration ratio of ROX, calculated as the ratio of the areas under SBF and plasma curves, was 63%. The SBF elimiantion half-life could not be calculated due to the lack of a clearly defined terminal elimination phase during the sampling period (24 hours). Saliva levels were always below the detection limit of the assay procedure.

Original languageEnglish
Pages (from-to)654-659
Number of pages6
JournalCurrent Therapeutic Research
Volume46
Issue number4
Publication statusPublished - 1989

Fingerprint

Roxithromycin
Suction
Blister
Skin
Saliva
Half-Life
Limit of Detection
Healthy Volunteers
Pharmacokinetics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Concia, E., Cruciani, M., Monzillo, V., Barzaghi, N., Bartucci, F., & Sassella, D. (1989). Roxithromycin penetration into skin suction blister fluid following multiple doses. Current Therapeutic Research, 46(4), 654-659.

Roxithromycin penetration into skin suction blister fluid following multiple doses. / Concia, E.; Cruciani, M.; Monzillo, V.; Barzaghi, N.; Bartucci, F.; Sassella, D.

In: Current Therapeutic Research, Vol. 46, No. 4, 1989, p. 654-659.

Research output: Contribution to journalArticle

Concia, E, Cruciani, M, Monzillo, V, Barzaghi, N, Bartucci, F & Sassella, D 1989, 'Roxithromycin penetration into skin suction blister fluid following multiple doses', Current Therapeutic Research, vol. 46, no. 4, pp. 654-659.
Concia, E. ; Cruciani, M. ; Monzillo, V. ; Barzaghi, N. ; Bartucci, F. ; Sassella, D. / Roxithromycin penetration into skin suction blister fluid following multiple doses. In: Current Therapeutic Research. 1989 ; Vol. 46, No. 4. pp. 654-659.
@article{08cacbe1cc624426b5081d831c876934,
title = "Roxithromycin penetration into skin suction blister fluid following multiple doses",
abstract = "Roxithromycin (ROX) concentrations in plasma, skin blister fluid (SBF), and saliva were investigated in six healthy male subjects after administration of 150 mg every 12 hours for 3.5 days (seven doses). Mean peak plasma concentration after the last dose was 5.4 ± 1.3 mg/L (range, 2.8 to 10.0 mg/L) and was attained at a mean time of 1.3 ± 0.2 hours. From the plasma concentration-time curve after the last dose the following pharmacokinetic parameters were calculated: elimination rate constant, 0.043 ± 0.005 L/hr; elimination half-life, 17.5 ± 2.2 hr; area under the concentration-time curve from zero to infinity; 106.4 ± 6.9 mg/L · hr. ROX showed a good penetration into SBF; the mean SBF/plasma concentration ratio ranged from 47{\%} to 106{\%} at two and 24 hours after administration, respectively. The mean penetration ratio of ROX, calculated as the ratio of the areas under SBF and plasma curves, was 63{\%}. The SBF elimiantion half-life could not be calculated due to the lack of a clearly defined terminal elimination phase during the sampling period (24 hours). Saliva levels were always below the detection limit of the assay procedure.",
author = "E. Concia and M. Cruciani and V. Monzillo and N. Barzaghi and F. Bartucci and D. Sassella",
year = "1989",
language = "English",
volume = "46",
pages = "654--659",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "4",

}

TY - JOUR

T1 - Roxithromycin penetration into skin suction blister fluid following multiple doses

AU - Concia, E.

AU - Cruciani, M.

AU - Monzillo, V.

AU - Barzaghi, N.

AU - Bartucci, F.

AU - Sassella, D.

PY - 1989

Y1 - 1989

N2 - Roxithromycin (ROX) concentrations in plasma, skin blister fluid (SBF), and saliva were investigated in six healthy male subjects after administration of 150 mg every 12 hours for 3.5 days (seven doses). Mean peak plasma concentration after the last dose was 5.4 ± 1.3 mg/L (range, 2.8 to 10.0 mg/L) and was attained at a mean time of 1.3 ± 0.2 hours. From the plasma concentration-time curve after the last dose the following pharmacokinetic parameters were calculated: elimination rate constant, 0.043 ± 0.005 L/hr; elimination half-life, 17.5 ± 2.2 hr; area under the concentration-time curve from zero to infinity; 106.4 ± 6.9 mg/L · hr. ROX showed a good penetration into SBF; the mean SBF/plasma concentration ratio ranged from 47% to 106% at two and 24 hours after administration, respectively. The mean penetration ratio of ROX, calculated as the ratio of the areas under SBF and plasma curves, was 63%. The SBF elimiantion half-life could not be calculated due to the lack of a clearly defined terminal elimination phase during the sampling period (24 hours). Saliva levels were always below the detection limit of the assay procedure.

AB - Roxithromycin (ROX) concentrations in plasma, skin blister fluid (SBF), and saliva were investigated in six healthy male subjects after administration of 150 mg every 12 hours for 3.5 days (seven doses). Mean peak plasma concentration after the last dose was 5.4 ± 1.3 mg/L (range, 2.8 to 10.0 mg/L) and was attained at a mean time of 1.3 ± 0.2 hours. From the plasma concentration-time curve after the last dose the following pharmacokinetic parameters were calculated: elimination rate constant, 0.043 ± 0.005 L/hr; elimination half-life, 17.5 ± 2.2 hr; area under the concentration-time curve from zero to infinity; 106.4 ± 6.9 mg/L · hr. ROX showed a good penetration into SBF; the mean SBF/plasma concentration ratio ranged from 47% to 106% at two and 24 hours after administration, respectively. The mean penetration ratio of ROX, calculated as the ratio of the areas under SBF and plasma curves, was 63%. The SBF elimiantion half-life could not be calculated due to the lack of a clearly defined terminal elimination phase during the sampling period (24 hours). Saliva levels were always below the detection limit of the assay procedure.

UR - http://www.scopus.com/inward/record.url?scp=0024468940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024468940&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 654

EP - 659

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 4

ER -